CD86 is a cell-surface protein that helps regulate T-cell activation. Expressed principally by antigen-presenting cells, it acts as a ligand for two receptors with different functions: CD28, which promotes T-cell activation, and CTLA-4, which restrains immune responses. CD86 therefore participates in both T-cell costimulation and the maintenance of immune tolerance. In humans, it is encoded by the CD86 gene on chromosome 3.
Molecular structure
CD86 belongs to the B7 family of immune-regulatory proteins and the immunoglobulin superfamily. It is a type I transmembrane glycoprotein, meaning that its amino-terminal region lies outside the cell, a single segment spans the cell membrane, and its carboxy-terminal tail lies inside the cell.
The extracellular region contains two immunoglobulin-like domains: a membrane-distal variable-like domain and a membrane-proximal constant-like domain. The extracellular portion mediates receptor binding and undergoes glycosylation. Its molecular organization enables CD86 on one cell to interact with receptors on an adjacent T cell.
CD86 is closely related in function to CD80, also called B7-1. Although both bind CD28 and CTLA-4, they differ in expression patterns, binding properties, and molecular organization. They are overlapping, rather than fully interchangeable, components of immune regulation.
Cellular expression
CD86 is expressed by professional antigen-presenting cells, including dendritic cells, macrophages, and B cells. Its abundance varies with cell type, tissue environment, and activation state. Some antigen-presenting cells display CD86 before stimulation and increase its expression after encountering microbial products or inflammatory signals.
During dendritic-cell maturation, increased CD86 expression commonly accompanies improved capacity to stimulate T cells. Signals associated with innate immunity, together with interactions between immune cells, help regulate this process. CD86 thus contributes to the connection between detection of a potential threat and the initiation of adaptive immunity.
CD86 is not exclusive to a single cell lineage or activation state. Its presence alone does not establish that a cell is functionally capable of initiating a particular T-cell response.
Role in T-cell activation
Activation of a naïve T cell normally requires more than recognition of an antigen. The T-cell receptor recognizes a peptide presented by a major histocompatibility complex molecule. CD86 binding to CD28 supplies an important additional costimulatory signal.
CD28 signaling supports several linked processes:
- Production of interleukin-2 and other activation-associated molecules.
- T-cell survival and proliferation.
- Metabolic changes that support growth and immune function.
- Development of effector responses in conjunction with other signals.
These effects depend on the broader cellular context, including antigen recognition, cytokine availability, and other activating or inhibitory receptors. CD86 is not an antigen-specific trigger and does not ordinarily activate naïve T cells independently of T-cell receptor engagement.
When antigen recognition occurs without adequate costimulation, the outcome may include impaired responsiveness, clonal anergy, or deletion rather than productive activation. Such outcomes depend on T-cell state and the surrounding signals; absence of CD86 alone does not necessarily produce tolerance, because CD80 and other pathways can contribute.
CTLA-4 and immune restraint
CD86 also binds CTLA-4, an inhibitory receptor expressed by activated conventional T cells and prominently associated with regulatory T cells. CTLA-4 binds the shared B7 ligands with greater affinity than CD28, helping limit access to costimulatory signals.
CTLA-4 can also capture CD86 and CD80 from the surface of another cell through a process called trans-endocytosis. Removal of these ligands reduces the antigen-presenting cell’s capacity to provide CD28-mediated costimulation. This mechanism contributes to peripheral immune tolerance.
The consequences of CD86 expression therefore depend partly on which receptor engages it. Describing CD86 solely as an activating molecule overlooks its participation in inhibitory regulation through CTLA-4.
Relationship to CD80
CD86 and CD80 were identified as distinct B7-family ligands in studies of T-cell costimulation in the early 1990s. CD86 is often available earlier during antigen-presenting-cell activation, whereas CD80 commonly increases later. This pattern is not universal and varies with cell type and stimulus.
Both molecules engage CD28 and CTLA-4, but differences in expression kinetics and receptor-binding behavior influence their contributions to immune responses. Their functions cannot be reduced to a strict division in which one always stimulates immunity and the other always suppresses it.
Research and clinical relevance
CD86 is commonly measured by flow cytometry and immunohistochemistry to characterize antigen-presenting cells and their responses to experimental conditions. It is frequently included in panels assessing dendritic-cell maturation or macrophage activation.
Interpretation requires additional markers and functional measurements. In particular, CD86 expression alone does not define a fixed macrophage subtype or demonstrate that a cell will stimulate T cells effectively.
The CD80/CD86–CD28 pathway is targeted by CTLA-4–immunoglobulin fusion proteins, including abatacept and belatacept. These agents bind CD80 and CD86 and reduce CD28-mediated costimulation. They are not selective inhibitors of CD86 alone.
CD86 is also studied in cancer, inflammation, transplantation, and autoimmune disease. Its biological significance depends on the expressing cell, the responding T-cell population, and the balance of stimulatory and inhibitory interactions; an increase in CD86 does not have a single, context-independent meaning.